Navigation Links
Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
Date:10/10/2007

SAN CARLOS, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that preclinical data for its proprietary product candidate NKTR-102 (PEG-irinotecan) will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Therapeutics in San Francisco, California on October 25, 2007. The presentations will highlight new results from preclinical trials of NKTR-102 in mouse models of colorectal, lung and breast cancers. NKTR-102 is a PEGylated form of irinotecan created using Nektar's innovative small molecule PEGylation technology platform and is in Phase 1 clinical development for the treatment of solid tumors.

In preclinical studies presented at ECCO 14 in September, NKTR-102 substantially suppressed tumor growth in an irinotecan-resistant mouse colorectal tumor model, while irinotecan-treated groups did not show a statistically significant decrease in tumor growth compared to controls. Further, administration of NKTR-102 resulted in a significantly improved pharmacokinetic profile for the active metabolite of irinotecan as compared to treatment with irinotecan.

"The studies for NKTR-102 continue to indicate that Nektar's small molecule PEGylation technology can be a powerful platform for improving chemotherapeutic agents," Tim Riley, Ph.D., Vice President of PEGylation Research at Nektar. "The new preclinical data in colorectal, lung and breast tumor models also highlights the promise of NKTR-102 to serve as a potentially new and powerful therapy in multiple solid tumor settings."

Two poster presentations are scheduled:

October 25, 2007 - 12:30 PM - 2:00 PM (PT); 5:30 - 7:30 PM (PT)

Poster Session C -- AACR-NCI-EORTC
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
2. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
3. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
4. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
5. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
6. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
7. Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/10/2009)... 10 /PRNewswire/ -- JumpStart Inc., the Northeas...erates the progress of high growth early-stage bus... commitment of $250,000 in Checkpoint Surgical, LL...H medical device company is developing and commerc...ulator. ,, (Logo: http://www.newscom.com/cgi...
(Date:11/10/2009).... and TOKYO, Nov. 10 Ironwood Phar...nnounced that they have entered into an agreement ... commercialize the investigational compound linacl... Taiwan, and Thailand. Linaclotide is currently in... for the treatment of irritable bowel syndrome wit...
(Date:11/9/2009)...if., Nov. 9 Thoratec Cor...e-based mechanical circulatory support therapies t...oday that it will be participating in the Third An...y, November 10. ,, The presentation by Gary F. ...ll begin at 8 a.m., Pacific Standard Time (11 a.m....
Breaking Medicine Technology:JumpStart Invests in Checkpoint Surgical 2JumpStart Invests in Checkpoint Surgical 3Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide 2Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide 3Fewer Genital Warts Thanks to HPV Vaccine Program 59521 1Fewer Genital Warts Thanks to HPV Vaccine Program 59521 2Local farmers in Africa to benefit from school meal programs 59518 1Local farmers in Africa to benefit from school meal programs 59518 2Local farmers in Africa to benefit from school meal programs 59518 3ASTRO Gildas Club Chicago join to promote cancer survivorship 59515 1
...hrax(TM) shows lifesaving potential -, - HGS on ...l Stockpile beginning in ...ences, Inc. (Nasdaq: HGSI ) today announced that ... life-saving potential of its human,monoclonal ant...show that a,single dose of ABthrax, administered w...
...Anthera Pharmaceuticals,Inc., a privately held bio...y drugs, announced today that the U.S. Food and Dr...evelopment has granted A-001,orphan drug status fo...ts,with sickle cell disease., A-001 is currently ...e,II clinical trial in the United States called IM...
Other Medicine Technology:New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies 2New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies 3New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies 4New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies 5New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies 6New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies 7Anthera's A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease 2Anthera's A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease 3
(Date:11/9/2009)...th Highlighted During Broadcast ,, WASHINGTON,...iance (LCA) announced that LCA staff, advocates an...ork Stock Exchange(TM) (NYSE) tomorrow afternoon a.../cgi-bin/prnh/20081016/LCALOGO ) ,, Five and a...e, Richard Heimler will mark the end of the day,s ...
(Date:11/9/2009)...wire/ -- The Churchill Centre today announced th...J.W. "Bill" Marriott for his lifelong commitment t...ket practices and fostering an open and transparen...ve his award at a ceremony and dinner on Tuesday, ...tel. ,, "This is a testament to how Bill Marri...
(Date:11/9/2009)...st equally, study finds, , , MONDAY, No...olving drug Plavix (clopidogrel) works about the s...cal trials has found. , "After this study, I ca... women with this very important drug," said Dr. Je...osis at New York University Langone Medical Center...
(Date:11/9/2009)...ences in mood despite similar weight loss , ...gh-fat, low-carbohydrate diet such as the popular ...r to help people lose pounds over the course of a ...s will result in long-term improvement in mood, ac...s of Internal Medicine . , People on both diets...
(Date:11/9/2009)...ow may be too late when it comes to preventing or ...Club, Inc. (Take Off Pounds Sensibly), the nonprof... (Vocus) November 9, 2009 -- Tomorrow...proving a diabetes condition, according to TOPS Cl... weight-loss support organization., , ,Diabetes is...
Breaking Medicine News(10 mins):Health News:Lung Cancer Alliance Staff and Advocates to Ring Closing Bell of New York Stock Exchange(TM) 2Health News:J.W. 'Bill' Marriott to Receive Churchill Centre Award For Leadership 2Health News:No Gender Gap Found for Clot-Busting Drug 2Health News:No Gender Gap Found for Clot-Busting Drug 3Health News:To Feel Better, Low-Fat Diet May Be Best 2Health News:To Feel Better, Low-Fat Diet May Be Best 3Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 2Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 3
...ticals Corp. (OTC Bulletin Board: RPTP), today ann...rate overview and clinical pipeline,updates at two...The 7th Annual BIO Investor Forum, to be held Octo...m PT) in Telegraph Hill. A live audio webcast...
...WLP ) announced,that Angela Braly, president and C... in Norfolk, Va. this evening. Ms. Braly focused o...em need to come together to improve,both access to...s to "fix what is broken, without breaking what,wo...
...Advance in AF-Ablation,Technology, CARLSBAD, Cali...day that two important abstracts which evaluated i...ation system were presented at the 5th,Annual Hear... as Dr. Simon James and Dr. John Bourke of the,Fre...
... The University,of Minnesota, Twin Cities shattere... given in a single day today (Tuesday, Oct. 28) by...y reports. The official number will,be released on...d was set in,November of 2006 in Sanford, Florida....
...r foreign markets and plans,Canadian rollout, LOS...n Board: UKMA), a lifestyle multimedia and consume... personal development, announced today that,its ex...r,s Association (ERA) Conference in Las Vegas duri...
...ty Determinations, WASHINGTON, Oct. 28 National ...cial Security Administration,s,new "Compassionate ... which,will accelerate the processing of disabilit...llaboration with professional,case managers and st...
Other Medicine News:Health News:Raptor Pharmaceuticals Corp. to Present at Two Upcoming Healthcare Conferences 2Health News:Raptor Pharmaceuticals Corp. to Present at Two Upcoming Healthcare Conferences 3Health News:Raptor Pharmaceuticals Corp. to Present at Two Upcoming Healthcare Conferences 4Health News:WellPoint President and CEO Angela Braly Appears at the Norfolk Forum 2Health News:Innovative Atrial Fibrillation (AF) Catheter Ablation System From Ablation Frontiers is Subject of Two Abstracts at Heart Rhythm Congress UK 2Health News:Innovative Atrial Fibrillation (AF) Catheter Ablation System From Ablation Frontiers is Subject of Two Abstracts at Heart Rhythm Congress UK 3Health News:Innovative Atrial Fibrillation (AF) Catheter Ablation System From Ablation Frontiers is Subject of Two Abstracts at Heart Rhythm Congress UK 4Health News:University Of Minnesota Gives 11,538 Flu Shots Tuesday, Shattering Guinness World Record for Most Flu Shots in a Single Day 2Health News:uKarma Reports Progress With International Distribution Agreement for Its Xflowsion DVD Series 2Health News:National Patient Advocate Foundation (NPAF) Commends SSA's New 'Compassionate Allowances Process' 2
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
Medicine Products: